Clinical Trial Update: Eltrombopag for Thrombocytopenia in Patients With Relapsed Multiple Myeloma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating eltrombopag for thrombocytopenia in patients with relapsed multiple myeloma was terminated; results were posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma
• Thrombocytopenia

Drugs mentioned

• Promacta (eltrombopag)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Thrombocytopenia, Multiple Myeloma | Phase 2 | Status: TERMINATED | Results posted: 2016-11-17